CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation

International Journal of Cancer

Volumn 137, Issue 1, 2015, Pages 50-60

  Jouve, Nathalie ^a   Bachelier, Richard ^a   Despoix, Nicolas ^a   Blin, Muriel G ^a   Matinzadeh, Maryam Khalili ^a   Poitevin, Stéphane ^a   Aurrand Lions, Michel ^b   Fallague, Karim ^a   Bardin, Nathalie ^a,d   Blot Chabaud, Marcel ^a   Vely, Frédéric ^c,d   Dignat George, Françoise ^a,d   Leroyer, Aurélie S ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

Author keywords

CD146; endothelium; FAK; metastasis

Indexed keywords

CD146 ANTIGEN; FOCAL ADHESION KINASE; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN C; CADHERIN; FOCAL ADHESION KINASE 1; LEUKOCYTE ANTIGEN; MCAM PROTEIN, MOUSE; PTK2 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; KNOCKOUT MOUSE; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR GROWTH; WILD TYPE; ANIMAL; CANCER TRANSPLANTATION; CYTOLOGY; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETICS; LUNG; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SECONDARY; TUMOR CELL CULTURE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD146; CADHERINS; ENDOTHELIUM, VASCULAR; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84930417222     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29370     Document Type: Article

References (49)

1. Lehmann JM, Riethmuller G, Johnson JP,. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989; 86: 9891-5.
2. Johnson JP, Lehmann JM, Stade BG, et al. Functional aspects of three molecules associated with metastasis development in human malignant melanoma. Invas Metastasis 1989; 9: 338-50.
3. Wu GJ, Wu MW, Wang SW, et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001; 279: 17-31.
4. Aldovini D, Demichelis F, Doglioni C, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 2006; 119: 1920-6.
5. Wu Z, Li J, Yang X, et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumour Biol 2012; 33: 1619-28.
6. Liu WF, Ji SR, Sun JJ, et al. CD146 Expression Correlates with Epithelial-Mesenchymal Transition Markers and a Poor Prognosis in Gastric Cancer. Int J Mol Sci 2012; 13: 6399-406.
7. Zabouo G, Imbert AM, Jacquemier J, et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res 2009; 11: R1.
8. Zeng Q, Li W, Lu D, et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 2012; 109: 1127-32.
9. Guezguez B, Vigneron P, Lamerant N, et al. Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor. J Immunol 2007; 179: 6673-85.
10. Melnikova VO, Bar-Eli M,. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 2006; 19: 395-405.
11. Wu GJ, Fu P, Wang SW, Wu MW,. Enforced expression of MCAM/MUC18 increases in vitro motility and invasiveness and in vivo metastasis of two mouse melanoma K1735 sublines in a syngeneic mouse model. Mol Cancer Res 2008; 6: 1666-77.
12. Luo Y, Zheng C, Zhang J, et al. Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene 2012; 31: 306-21.
13. Watson-Hurst K, Becker D,. The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 2006; 5: 1375-82.
14. Wu GJ, Wu MW, Wang C, Liu Y,. Enforced expression of METCAM/MUC18 increases tumorigenesis of human prostate cancer LNCaP cells in nude mice. J Urol 2011; 185: 1504-12.
15. Zeng G, Cai S, Liu Y, Wu GJ,. METCAM/MUC18 augments migration, invasion, and tumorigenicity of human breast cancer SK-BR-3 cells. Gene 2012; 492: 229-38.
16. Orr FW, Wang HH, Lafrenie RM, et al. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000; 190: 310-29.
17. Voura EB, Sandig M, Kalnins VI, Siu C,. Cell shape changes and cytoskeleton reorganization during transendothelial migration of human melanoma cells. Cell Tissue Res 1998; 293: 375-87.
18. Bardin N, Anfosso F, Masse JM, et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 2001; 98: 3677-84.
19. George F, Brisson C, Poncelet P, et al. Rapid isolation of human endothelial cells from whole blood using S-Endo1 monoclonal antibody coupled to immuno-magnetic beads: demonstration of endothelial injury after angioplasty. Thromb Haemost 1992; 67: 147-53.
20. Solovey AN, Gui L, Chang L, et al. Identification and functional assessment of endothelial P1H12. J Lab Clin Med 2001; 138: 322-31.
21. Anfosso F, Bardin N, Frances V, et al. Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). J Biol Chem 1998; 273: 26852-6.
22. Anfosso F, Bardin N, Vivier E, et al. Outside-in signaling pathway linked to CD146 engagement in human endothelial cells. J Biol Chem 2001; 276: 1564-9.
23. Bu P, Gao L, Zhuang J, et al. Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappaB activation. Mol Cancer Ther 2006; 5: 2872-8.
24. Jiang T, Zhuang J, Duan H, et al. CD146 is a co-receptor for VEGFR-2 in tumor angiogenesis. Blood 2012; 120: 2330-9.
25. Zeng Q, Wu Z, Duan H, et al. Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice. Protein Cell 2014; 5: 445-46.
26. Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 2003; 90: 915-20.
27. Harhouri K, Kebir A, Guillet B, et al. Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 2010; 115: 3843-51.
28. Kebir A, Harhouri K, Guillet B, et al. CD146 short isoform increases the proangiogenic potential of endothelial progenitor cells in vitro and in vivo. Circ Res 2010; 107: 66-75.
29. Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003; 102: 184-91.
30. Bardin N, Blot-Chabaud M, Despoix N, et al. CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler, Thromb Vasc Biol 2009; 29: 746-53.
31. Arguello F, Baggs RB, Frantz CN,. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48: 6876-81.
32. Miles AA, Miles EM,. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J Physiol 1952; 118: 228-57.
33. Marelli-Berg FM, Peek E, Lidington EA, et al. Isolation of endothelial cells from murine tissue. J Immunol Methods 2000; 244: 205-15.
34. Despoix N, Walzer T, Jouve N, et al. Mouse CD146/MCAM is a marker of natural killer cell maturation. Eur J Immunol 2008; 38: 2855-64.
35. Chen XL, Nam JO, Jean C, et al. VEGF-induced vascular permeability is mediated by FAK. Dev Cell 2012; 22: 146-57.
36. Cangara HM, Ishida T, Hara T, et al. Role of endothelial cell-selective adhesion molecule in hematogeneous metastasis. Microvasc Res 2010; 80: 133-41.
37. Langer HF, Orlova VV, Xie C, et al. A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis. Cancer Res 2011; 71: 4096-105.
38. Ouhtit A, Gaur RL, Abd Elmageed ZY, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 2009; 1795: 130-6.
39. Ballmer-Hofer K, Andersson AE, Ratcliffe LE, Berger P,. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 2011; 118: 816-26.
40. Jin F, Hagemann N, Brockmeier U, et al. LDL attenuates VEGF-induced angiogenesis via mechanisms involving VEGFR2 internalization and degradation following endosome-trans-Golgi network trafficking. Angiogenesis 2013; 16: 625-37.
41. Ansieau S, Hinkal G, Thomas C, et al. Early origin of cancer metastases: dissemination and evolution of premalignant cells. Cell Cycle 2008; 7: 3659-63.
42. Paez D, Labonte MJ, Bohanes P, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2012; 18: 645-53.
43. Pantel K, Brakenhoff RH,. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-56.
44. Rocken M,. Early tumor dissemination, but late metastasis:insights into tumor dormancy. J Clin Invest 2010; 120: 1800-3.
45. Purdue MP, Freeman LE, Anderson WF, Tucker MA,. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008; 128: 2905-8.
46. Jean C, Chen XL, Nam JO, et al. Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function. J Cell Biol 2014; 204: 247-63.
47. Megison ML, Stewart JE, Nabers HC, et al. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis 2013; 30: 555-68.
48. Tavora B, Reynolds LE, Batista S, et al. Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature 2014; 514: 112-6.
49. Walsh C, Tanjoni I, Uryu S, et al. Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. Cancer Biol Ther 2010; 9: 778-90.